Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?
Open Access
- 1 January 2008
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 47 (1) , 110-119
Abstract
Background. Chemotherapy with gemcitabine and cisplatin (GC) is an active regimen in advanced transitional cell carcinoma (TCC). Traditionally, GC has been administered as a 4-week schedule. However, an alternative 3-week schedule may be more feasible. Long-term survival data for the alternative 3-week schedule and comparisons of the feasibility and toxicity between the two schedules have not previously been published. Material and methods. We performed a retrospective analysis of patients with stage IV TCC, treated with GC by a standard 4-week or by an alternative 3-week schedule. Results. A total of 212 patients received GC (3-week; n=151, 4-week; n=61). We found no statistical differences in overall survival between the two schedules (hazard ratio 1.15, 95% CI 0.83–1.59), p=0.40). Five-year survival rates were 14.9% and 11.8% for the 3- and 4-week schedule, respectively (p=0.94). Response rates were 59.7% and 55.6%, respectively (p=0.61). Toxicity was less pronounced in the 3-week schedule with regards to neutropenia, thrombocytopenia, and transfusion rates. Hematologic toxicity at day 15 in the 4-week schedule was common, leading to dose omissions in 47% of cycles. Dose intensity for gemcitabine was accordingly lower in the 4 week-schedule. The higher dose intensity of cisplatin in the 3-week schedule, did not lead to increased renal toxicity. In 13 patients with impaired renal function, cisplatin was split into 2 days, which was feasible and efficient. Conclusion. Efficacy parameters for the GC 3-week schedule were comparable to those for the 4-week schedule, whereas toxicity was less pronounced. The 3-week schedule may be an effective and feasible alternative GC-schedule.Keywords
This publication has 19 references indexed in Scilit:
- A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancerLung Cancer, 2006
- Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinomaHead & Neck, 2006
- Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer CentersAnti-Cancer Drugs, 2006
- Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: Result of a dose-intensity studyInvestigational New Drugs, 2006
- Phase II Study of Fixed Dose Rate Gemcitabine With Cisplatin for Metastatic Adenocarcinoma of the PancreasJournal of Clinical Oncology, 2006
- Phase II Study of Gemcitabine and Cisplatin in Patients with Advanced or Metastatic Bladder Cancer: Long-Term Follow-Up of a 3-Week RegimenOncology, 2005
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trialLung Cancer, 2003
- GEMCITABINE PLUS CISPLATIN FOR ADVANCED TRANSITIONAL CELL CARCINOMA OF THE URINARY TRACT: A PHASE II MULTICENTER TRIALJournal of Urology, 2000
- A Phase II Study of Gemcitabine and Cisplatin in Patients with Advanced, Persistent, or Recurrent Squamous Cell Carcinoma of the CervixGynecologic Oncology, 2000